Literature DB >> 6938305

A phase II study of aclacinomycin A in acute leukemia in adults.

K Yamada, T Nakamura, T Tsuruo, T Kitahara, T Maekawa, Y Uzaka, S Kurita, T Masaoka, F Takaku, Y Hirota, I Amaki, S Osamura, M Ito, N Nakano, M Oguro, J Inagaki, K Onozawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6938305     DOI： 10.1016/s0305-7372(80)80033-8

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  7 in total

Review 1.  Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.

Authors:  W Hiddemann; T Büchner
Journal:  Blut       Date:  1990-03

2.  Aclacinomycin A in the treatment of multiple myeloma: a Southwest Oncology Group study.

Authors:  C Karanes; J Crowley; L Sawkar; B L Tranum; W J Hicks; J D Bonnet; L Dabich; B W Dana; S Salmon
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

3.  Phase II trial of aclacinomycin A in acute leukemia and various solid tumors.

Authors:  J Schütte; N Niederle; S Seeber
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

4.  TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.

Authors:  Meenu Jain; Lisa Zhang; Mei He; Ya-Qin Zhang; Min Shen; Electron Kebebew
Journal:  Endocr Relat Cancer       Date:  2013-05-21       Impact factor: 5.678

5.  Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma.

Authors:  K G Louie; T C Hamilton; B C Behrens; K R Grotzinger; W M McKoy; C E Myers; R C Young; R F Ozols
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Activity of the pyrazoloacridines against multidrug-resistant tumor cells.

Authors:  J Sebolt; M Havlick; K Hamelehle; J Nelson; W Leopold; R Jackson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 7.  The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach.

Authors:  A C Sartorelli
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.